Perceptive Advisors buys $32,688,383 stake in Lion Biotechnologies Inc (LBIO)

Lion Biotechnologies Inc (LBIO) : Perceptive Advisors scooped up 824,720 additional shares in Lion Biotechnologies Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 11, 2016. The investment management firm now holds a total of 3,611,976 shares of Lion Biotechnologies Inc which is valued at $32,688,383.Lion Biotechnologies Inc makes up approximately 2.40% of Perceptive Advisors’s portfolio.

Other Hedge Funds, Including , Alliancebernstein boosted its stake in LBIO in the latest quarter, The investment management firm added 28,400 additional shares and now holds a total of 39,600 shares of Lion Biotechnologies Inc which is valued at $358,380.Blackrock Fund Advisors boosted its stake in LBIO in the latest quarter, The investment management firm added 22,544 additional shares and now holds a total of 1,807,203 shares of Lion Biotechnologies Inc which is valued at $16,355,187. First Eagle Investment Management added LBIO to its portfolio by purchasing 150,000 company shares during the most recent quarter which is valued at $1,336,500. Simplex Trading added LBIO to its portfolio by purchasing 72,340 company shares during the most recent quarter which is valued at $593,188. Lion Biotechnologies Inc makes up approx 0.07% of Simplex Trading’s portfolio.Creative Planning boosted its stake in LBIO in the latest quarter, The investment management firm added 350 additional shares and now holds a total of 1,000 shares of Lion Biotechnologies Inc which is valued at $8,340.

Lion Biotechnologies Inc opened for trading at $9.23 and hit $9.24 on the upside on Tuesday, eventually ending the session at $9.19, with a gain of 0.44% or 0.04 points. The heightened volatility saw the trading volume jump to 1,48,830 shares. Company has a market cap of $537 M.

Lion Biotechnologies Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing adoptive cell therapy (ACT) using autologous tumor infiltrating lymphocytes (TILs) for the treatment of metastatic melanoma and other solid cancers. The Company’s program is an adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL) which are T cells derived from patients’ tumors for the treatment of metastatic melanoma. Once the TILs have been multiplied to a sufficient number ex vivo and after the patient has completed the non-myeloablative chemotherapeutic regimen the TILs are infused into the patient along with a high dose of interleukin2 (IL2) a protein that stimulates the immune system.

Leave a Reply

Lion Biotechnologies Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Lion Biotechnologies Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.